Upneeq® Wins 2024 Shape Skin Award, “Best for Lift”, in the Professional Treatment Category
May 17 2024 - 2:34PM
Business Wire
RVL Pharmaceuticals announced today that its prescription eye
drop, Upneeq® (oxymetazoline hydrochloride ophthalmic solution),
0.1% has been selected as a 2024 Shape Skin Award winner by Shape
Magazine, named “Best for Lift” in the professional category. This
is the third Shape award for Upneeq. The product was also named as
a "Best Professional Grade'' treatment by editors in 2022 and
received a 2023 Shape Beauty Award for “Best In-Office" treatments.
Upneeq is FDA approved for the treatment of acquired ptosis (droopy
eyelids) in adults.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240517409527/en/
(Photo: Business Wire)
For the 2024 Shape Skin Awards, editors tested over 225
expert-backed face, body, and hair products, facial devices, and
aesthetic medical treatments, consulting with board-certified
industry experts and researching over a dozen published skincare
studies to inform the winning selections. Products were evaluated
for their effectiveness, innovation, and performance. 37 winners
were ultimately chosen, and judges awarded Upneeq for its subtle
but noticeable lift for droopy eyelids.
“We are incredibly grateful to Shape Magazine for recognizing
Upneeq as a top player in the beauty industry for the third year in
a row and are honored to be named as the ‘Best for Lift’,” said
Jennifer Hanlon, Head of Digital Marketing and Consumer Technology
at RVL Pharmaceuticals. “Shape is an empowering and trusted voice
in health and beauty with a committed community to quality
self-care. Being a part of this awards program, supported by
editors and industry experts alike, is a testament to Upneeq’s
performance and impact.”
Upneeq is a one-of-a-kind, daily eyedrop for adult patients with
acquired ptosis that lifts the eyelid to create a more open eye
area. Upneeq is available at eye care, dermatology, plastic surgery
and medical aesthetic practices nationwide, as well as
SkinSolutions.MD via telehealth appointment. In clinical trials,
Upneeq demonstrated statistically significant improvements compared
to placebo in both superior visual field and eyelid lift, as
measured in two pivotal double-masked efficacy studies. The most
common adverse reactions with Upneeq (occurring in 1-5% of
patients) were eye inflammation, eye redness, dry eye, blurred
vision, eye pain at time of use, eye irritation, and headache. For
more information, visit www.Upneeq.com
IMPORTANT SAFETY INFORMATION
What is Upneeq®? Upneeq® (oxymetazoline hydrochloride
ophthalmic solution), 0.1% is a prescription eyedrop used to treat
acquired blepharoptosis (low-lying lids) in adults.
What are the most common side effects of Upneeq®?
- The most common adverse reactions with Upneeq® (occurring in
1-5% of patients) were eye inflammation, eye redness, dry eye,
blurred vision, eye pain at time of use, eye irritation, and
headache.
What warnings and precautions are associated with Upneeq®?
- Upneeq® is a type of medication that may affect your blood
pressure. If you have heart disease, uncontrolled high or low blood
pressure, or feel faint at rest or when quickly standing up, you
should call your doctor if your symptoms get worse.
- Upneeq® may increase the risk of eye pressure due to fluid
buildup (angle-closure glaucoma) in patients with untreated
narrow-angle glaucoma. Call your doctor immediately if you feel
increased pressure in your eye after using Upneeq®.
- Do not let the tip of the Upneeq® vial touch your eye or any
other surface. This can help prevent eye injury or contamination.
Each Upneeq® vial is for one-time use and should be discarded after
being used.
- Low-lying lids may also be related to conditions such as stroke
and/or brain aneurysm, Horner syndrome, myasthenia gravis, loss of
the ability to move eye muscles, eye infection and eye tumors. Tell
your doctor if you have any of these conditions.
- Patients with reduced blood flow to the brain or heart, or
patients who experience eye or mouth dryness due to an immune
system disorder (Sj�gren’s syndrome), should use care when taking
Upneeq®. Call your doctor immediately if you feel your symptoms may
be getting worse.
What should my doctor know about before prescribing me
Upneeq®?
- Your doctor should review your full medical history before
prescribing Upneeq®.
- Upneeq® belongs to a class of medication (alpha-adrenergic
agonists) that may affect your blood pressure. Use Upneeq®
carefully if you currently take an alpha-adrenergic agonist
medication to treat heart disease or an enlarged prostate. Patients
taking beta-blockers, or other medications to treat hypertension or
an abnormal heartbeat, should also be careful when using
Upneeq®.
- Patients who use a certain class of antidepressant medication
(monoamine oxidase inhibitors) should also be careful when using
Upneeq®, as it may affect the way your body absorbs the
medication.
This is a summary of the most important safety information for
Upneeq®. For more in-depth safety information, please review the
full Prescribing Information for Upneeq®.
To report a side effect, contact RVL Pharmaceuticals at
1-877-482-3788. You may also report side effects to the FDA by
calling 1-800-FDA-1088 or visit www.fda.gov/medwatch.
About RVL Pharmaceuticals,
Inc.
RVL Pharmaceuticals, Inc. is a specialty pharmaceutical company
focused on the commercialization of Upneeq® (oxymetazoline
hydrochloride ophthalmic solution), 0.1%, for the treatment of
acquired blepharoptosis, or low-lying eyelids, in adults. Upneeq is
the first non-surgical treatment option approved by the FDA for
acquired blepharoptosis.
About Shape
Shape is an award-winning digital fitness, wellness, and beauty
destination that offers inclusive, trusted, and empowering
expert-led guidance and advice for anyone at any point in their
wellness journey. Their library of more than 11,000 stories reaches
more than 7 million readers monthly who want to prioritize their
health, have fun, and lead an active lifestyle while also cutting
through the noise of quick fixes and unvetted fads.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240517409527/en/
Colleen Ketchum Email: Colleen.ketchum@precisionvh.com